Drug Shortage Report for HALOPERIDOL INJECTION, USP

Last updated on 2022-09-14 History
Report ID 163518
Drug Identification Number 02406411
Brand name HALOPERIDOL INJECTION, USP
Common or Proper name HALOPERIDOL INJECTION, USP
Company Name FRESENIUS KABI CANADA LTD
Market Status MARKETED
Active Ingredient(s) HALOPERIDOL
Strength(s) 5MG
Dosage form(s) SOLUTION
Route of administration INTRAMUSCULAR INTRAMUSCULAR
Packaging size 1 ml
ATC code N05AD
ATC description ANTIPSYCHOTICS
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date 2022-07-01
Actual start date 2022-07-01
Estimated end date 2022-09-05
Actual end date 2022-09-13
Shortage status Resolved
Updated date 2022-09-14
Company comments Fresenius Kabi Canada regrets to advise that due to production and shipping delays, we will be encountering a supply interruption on our Haloperidol Injection, USP 5 mg/mL MD Vial 1 mL effective July 1, 2022 until Sep 5, 2022
Health Canada comments
Tier 3 Status No
Contact Address 165 GALAXY BLVD, SUITE 100
TORONTO, ONTARIO
CANADA M9W 0C8
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v8 2022-09-14 English Compare
v7 2022-09-12 French Compare
v6 2022-09-12 English Compare
v5 2022-08-21 French Compare
v4 2022-08-21 English Compare
v3 2022-07-02 English Compare
v2 2022-06-27 French Compare
v1 2022-06-27 English Compare

Showing 1 to 8 of 8